SITC Publishes Guidelines on Immune Effector Cell-Related Adverse Events
The Society for Immunotherapy of Cancer (SITC) published The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events in the Journal for ImmunoTherapy of Cancer (JITC). Developed by an expert panel, the guideline includes recommendations for risk assessment, identification, and management for clinically significant side effects associated with immune effector cells (IECs).
This guideline was created with the assistance of several organizations, including FACT. For more details about its purpose and scope, read the full press release from SITC.
